We are live on ! Find out more
KRTX

Karuna Therapeutics, Inc. Common Stock
KRTX

Delisted

KRTX was delisted on the 15th of March, 2024.

Back to rankings

2 hedge funds and large institutions have $270K invested in Karuna Therapeutics, Inc. Common Stock in 2024 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 325 closing their positions.

New
Increased
Maintained
Reduced
Closed

99% less funds holding

Funds holding: 328 → 2 (-326)

100% less funds holding in top 10

Funds holding in top 10: 26 → 0 (-26)

100% less capital invested

Capital invested by funds: $12B → $270K (-$12B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 325

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
2
Holders Change
-326
Holders Change %
-99.39%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
-26
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
325
Calls
$2K
Puts
–
Net Calls
+$2K
Net Calls Change
-$46.5M

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Capital International Investors
Capital International Investors
California
-$1.34B
2
Vanguard Group
Vanguard Group
Pennsylvania
-$1.02B
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$907M
4
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
-$858M
5
BlackRock
BlackRock
New York
-$638M
Name Holding Trade Value Shares
Change 		Change in
Stake
IA
1
IFP Advisors
Florida
$269K -$952 -3 -0.4%
S
2
Sachetta
Massachusetts
$317 – – –
Capital International Investors
3
Capital International Investors
California
– -$1.34B -4,227,102 Closed
Vanguard Group
4
Vanguard Group
Pennsylvania
– -$1.02B -3,224,786 Closed
Fidelity Investments
5
Fidelity Investments
Massachusetts
– -$907M -2,865,994 Closed
T. Rowe Price Investment Management
6
T. Rowe Price Investment Management
Maryland
– -$858M -2,709,629 Closed
BlackRock
7
BlackRock
New York
– -$638M -2,015,374 Closed
T. Rowe Price Associates
8
T. Rowe Price Associates
Maryland
– -$621M -1,961,587 Closed
SI
9
Sofinnova Investments
California
– -$437M -1,381,149 Closed
Wellington Management Group
10
Wellington Management Group
Massachusetts
– -$359M -1,134,046 Closed
PCM
11
Pentwater Capital Management
Florida
– -$337M -1,066,200 Closed
GA
12
General Atlantic
New York
– -$312M -986,710 Closed
State Street
13
State Street
Massachusetts
– -$308M -974,643 Closed
PBPIA
14
Pivotal bioVenture Partners Investment Advisor
California
– -$252M -797,008 Closed
HI
15
HBK Investments
Texas
– -$201M -635,960 Closed
Geode Capital Management
16
Geode Capital Management
Massachusetts
– -$180M -569,722 Closed
FCM
17
Farallon Capital Management
California
– -$165M -522,000 Closed
RSCM
18
Rock Springs Capital Management
Maryland
– -$163M -515,024 Closed
UBS Group
19
UBS Group
Switzerland
– -$134M -422,178 Closed
AllianceBernstein
20
AllianceBernstein
Tennessee
– -$119M -377,155 Closed
WP
21
Woodline Partners
California
– -$113M -357,473 Closed
Brown Advisory
22
Brown Advisory
Maryland
– -$105M -333,144 Closed
Norges Bank
23
Norges Bank
Norway
– -$104M -328,067 Closed
Invesco
24
Invesco
Georgia
– -$101M -319,136 Closed
Balyasny Asset Management
25
Balyasny Asset Management
Illinois
– -$100M -315,892 Closed
1
2 3 4 5

KRTX Hedge Fund Activity: Q1 2024 in Review

2 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Karuna Therapeutics, Inc. Common Stock (KRTX) for Q1 2024, worth a combined $270K — down 100% from $12B a quarter earlier.

Sellers outnumbered buyers: 325 funds closed out of KRTX and 0 opened new positions — a net loss of 325 holders — while 1 trimmed existing stakes and 0 added.

The largest seller was Capital International Investors, exiting entirely with an estimated $1.34B sold.

  • 2 institutional investors held Karuna Therapeutics, Inc. Common Stock (KRTX) as of Q1 2024, down from 328 in Q4 2023.
  • Funds reported $270K of Karuna Therapeutics, Inc. Common Stock stock for Q1 2024, down 100% quarter-over-quarter.
  • 0 funds opened new Karuna Therapeutics, Inc. Common Stock positions in Q1 2024 and 325 closed out, a net change of -325 holders.
  • The largest Karuna Therapeutics, Inc. Common Stock seller in Q1 2024 was Capital International Investors, an estimated $1.34B sold.

Based on aggregated 13F filings for Q1 2024.